Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HOOKIPA PHARMA INC.

(HOOK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Hookipa Pharma : Merck Collaborate on Head, Neck Cancer Combo Therapy Development

09/15/2021 | 07:53am EDT


ę MT Newswires 2021
All news about HOOKIPA PHARMA INC.
10/14HOOKIPA PHARMA : announces publication on the benefits of its novel arenaviral immunothera..
AQ
10/14HOOKIPA Pharma Inc. Announces Publication on the Benefits of its Novel Arenaviral Immun..
CI
09/16HOOKIPA PHARMA : announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ.,..
AQ
09/15HOOKIPA PHARMA : Merck Collaborate on Head, Neck Cancer Combo Therapy Development
MT
09/15HOOKIPA PHARMA : announces clinical collaboration with Merck & Co., Inc.,áKenilworth, NJ.,..
AQ
09/15Hookipa Working With Merck in Advanced Head and Neck Cancers
DJ
09/07HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
GL
08/18HOOKIPA PHARMA : Morgan Stanley Adjusts Price Target on HOOKIPA Pharma to $18 From $19, Ma..
MT
08/12HOOKIPA PHARMA : Reports Second Quarter 2021 Financial Results and Recent Highlights (Form..
PU
08/12HOOKIPA PHARMA : Management's Discussion and Analysis of Financial Condition and Results o..
AQ
More news
Analyst Recommendations on HOOKIPA PHARMA INC.
More recommendations
Financials (USD)
Sales 2021 20,8 M - -
Net income 2021 -75,3 M - -
Net cash 2021 91,8 M - -
P/E ratio 2021 -2,37x
Yield 2021 -
Capitalization 160 M 160 M -
EV / Sales 2021 3,28x
EV / Sales 2022 3,30x
Nbr of Employees 123
Free-Float 78,8%
Chart HOOKIPA PHARMA INC.
Duration : Period :
HOOKIPA Pharma Inc. Technical Analysis Chart | HOOK | US43906K1007 | MarketScreener
Technical analysis trends HOOKIPA PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 5,36 $
Average target price 22,71 $
Spread / Average Target 324%
EPS Revisions
Managers and Directors
J÷rn Aldag Chief Executive Officer & Director
Thomas Lingelbach President
Reinhard Kandera Chief Financial Officer & Director
Jan G. J. van de Winkel Chairman
Igor Matushansky Chief Medical Officer & Global Head-Research
Sector and Competitors
1st jan.Capi. (M$)
HOOKIPA PHARMA INC.-51.67%160
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657